Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum.

It’s not just investments that are gaining traction. Recent approvals are changing the game, with Iovance and Adaptimmune making strides in treating solid tumours, Kite securing first-line treatment approval, and donor cell therapies, demonstrating success in putting autoimmune diseases into remission. The industry is brimming with new hope!

The 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in cell therapy. Join us to collaborate, innovate, and overcome the shared challenges of safety concerns, high cost of goods, effective tumour targeting, and more. Let’s work together to drive success in clinical trials, secure regulatory approvals, and position cell therapy as the first-line treatment for oncological and non-oncological indications.

URLs:
Website: https://go.evvnt.com/2712222-0?pid=11140
Brochure: https://go.evvnt.com/2712222-3?pid=11140

Prices:
Conference + Autoimmune OR Regulatory Focus Day – Drug Developer : GBP 3597.00,
Conference Only – Drug Developer: GBP 2599.00,
Conference + Autoimmune OR Regulatory Focus Day – Start Up and Academic: GBP 2997.00,
Conference Only – Start Up and Academic: GBP 2199.00,
Conference + Autoimmune OR Regulatory Focus Day – Solution and Service Provider: GBP 5097.00,
Conference Only – Solution and Service Provider: GBP 3899.00

Speakers: Aaron Edwards – Chief Executive Officer and Co-Founder – KiraGenBio, Adrian Bot – Chief Scientific Officer – Capstan Therapeutics, Ali Mohamed – Senior Vice President – CMC Immatics, Allen Feng – Founder and Chief Scientific Officer – HebeCell Corp, Andrew O’Leary – Senior Scientist Analytical Development – Resolution Therapeutics, Birk Vanderween – Senior Vice President, Global Manufacturing and Supply – Legend Biotech, Blake Aftab – Chief Scientific Officer – Adicet Bio, Chris Barkey – Chief Executive Officer – Swissfinity Group, Christopher Murriel – Vice President, Pre-Clinical Pharmacology – ArsenalBio, Cokey Nguyen – President and Chief Executive Officer – Atara Biotherapeutics, Danielle Quarles – Executive Director, Clinical Operations – Sana Biotechnology, David Fontana – Chief Operating Officer – Umoja Biopharma, Deep Shah – Senior Director, Regulatory Affairs – Sana Biotechnology, Felix Lorenz – Chief Executive Officer / Chief Scientific Officer – Captain T Cell, Franco Locatelli – Professor, Catholic University of Sacred Heart – Bambion Gesu Children’s Hospital, Frederik De Vos – Senior Director, Quality Operations – Johnson and Johnson, George Coukos – Director, Department of Oncology – University of Lausane, Greg Deener – Chief Executive Officer – iCell Gene Therapeutics, Gwendolyn Binder – President, Science and Technology – Cabaletta Bio, Hemant Dhamne – Associate Director, Process Development – Autolus, Houman Dehghani – Vice President, Process and Analytical Development – Cabaletta Bio, Hugh Salter – Chief Scientific Officer – Anocca, Jeff Liter – Founder and Chief Executive Officer – Luminary Therapeutics, Jeffrey Jones – Chief Medical Officer – Cullinan Therapeutics, Jenell Volkov – Senior Director, Translational Medicine – Cabaletta Bio, Jiri Eitler – Group Leader – TU Dresden, Kate Rochlin – Chief Operating Officer – IN8Bio, Katja Mohrs – Principal Scientist – Regeneron, Kerstin Papenfuss – Head Pharma Team – Deep Science Ventures, Laurent Poirot – Senior Vice President, Immunology – Cellectis, Leon Spijkers – Chief Executive Officer – Korecyte Bio, Leopold Sellner – Senior Director – Takeda, Luise Weigand – Head Of Research – Zelluna Immunotherapy, Marc Davies – Vice President, Research and Development – Leucid Bio, Marc Guell – ICREA Research Professor – University Pompeau Fabro, Marlene Carrasco Alfonso – Global Head Immunology Cell Therapy – AstraZeneca, Michael Bauer – Partner, Novo Holdings – Venture Investments, Nancy Boman – Chief Regulatory Officer – Adicet Bio, Natalie Telizki – Chief Executive Officer – Swissfinity Group, Omer Dushek – Founder – MatchBio, Peggy Sotiropoulou – Chief Scientific Officer – T-knife Therapeutics, Pierre Springuel – PhD Candidate – UCL, Rachel East – Research Analyst – Beacon, Raha Jahromi – Associate Director – Kite, A Gilead Company, Raphaël OGNAR President and CEO, Co-founder – NKILT Therapeutics, Rhine Shen – Senior Director, Translational Medicine Kite, A Gilead Company, Senior Director, Translational Medicine – Kite, A Gilead Company, Rudolf Übelhart – Chief Scientific Officer – Vanudis, Shayoni Dutta – Data Science Manager – GSK, Stefanos Theoharis – Chief Executive Officer – OneChain Immunotherapeutics, Tiffany Chen – Vice President, Discovery – GentiBio, Vaishali Shukla – Head of Cell Therapy – Eli Lilly

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Clinical

Time: 8:00 am to 5:30 pm